Close Menu

NEW YORK – T2 Biosystems disclosed in a filing with the Securities and Exchange Commission on Wednesday it received a warning letter from the Nasdaq Stock Market because its stock price has been below $1 for at least 30 consecutive business days.

As a result, the company could face delisting action by Nasdaq. T2 Bio has until Oct. 5 to avoid delisting, and the firm said it will monitor the bid price of its common stock and consider potential options, including performing a reverse stock split.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.